Meeting
2020 ASCO Virtual Scientific Program
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
Presenter
Jingran Ji, MD
University of California Davis Comprehensive Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9570)
DOI
10.1200/JCO.2020.38.15_suppl.9570
Abstract #
9570
Poster Bd #
336
Abstract Disclosures
Similar Videos & Slides
Speaker: Carlos H. Barrios, MD
Videos & Slides
2017 ASCO Annual Meeting
Osimertinib compared to docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small cell lung cancer.
Speaker: Keke Nie
Speaker: David P. Ryan, MD
Videos & Slides
2024 ASCO Breakthrough
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
Speaker: Makoto Nishio, MD, PhD